703 related articles for article (PubMed ID: 18164542)
1. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological treatment of multiple sclerosis].
Myhr KM
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
Pula JH; Javed A
Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
[TBL] [Abstract][Full Text] [Related]
4. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
5. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
[TBL] [Abstract][Full Text] [Related]
7. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the treatment of multiple sclerosis?].
Tackenberg B; Himmerich H; Wellek A; Oertel WH; Sommer N
MMW Fortschr Med; 2007 May; 149 Suppl 2():51-5. PubMed ID: 17724968
[TBL] [Abstract][Full Text] [Related]
11. [Recent therapeutic strategy for multiple sclerosis].
Itoyama Y
Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
[TBL] [Abstract][Full Text] [Related]
12. Current disease-modifying treatment of multiple sclerosis.
Derwenskus J
Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
[TBL] [Abstract][Full Text] [Related]
13. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis.
Mattson DH
Semin Neurol; 2002 Mar; 22(1):17-25. PubMed ID: 12170390
[TBL] [Abstract][Full Text] [Related]
14. Rationale for the use of mitoxantrone in multiple sclerosis.
Edan G; Morrissey S; Le Page E
J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
[TBL] [Abstract][Full Text] [Related]
15. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
; Rieckmann P
Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
[TBL] [Abstract][Full Text] [Related]
16. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
17. [New approaches in research of therapy of multiple sclerosis].
Hemmer B; Cepok S; Nessler S; Sommer N
Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
Stuart WH
Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
[TBL] [Abstract][Full Text] [Related]
19. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
20. A practical approach to immunomodulatory therapy for multiple sclerosis.
Burks JS
Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
